Comparison of Indolidan Analog Binding Sites of Drug Antibody and Sarcoplasmic Reticulum with Inhibition of Cyclic AMP Phosphodiesterase

References

• Weishaar R. E., Quande M. M., Schenden J. A., Evans D. B. Relationship between inhibition of cardiac muscle phosphodiesterase, changes in cyclic nucleotide levels and contractile responses for CI-914 and other novel cardiotonics. J. Cyclic Nucleotide Protein Phosphorylation Res. 1985; 10: 551–564
   PubMedGoogle Scholar
• Colucci W. S., Wright R. F., Braunwald E. New positive inotropic agents in the treatment of congestive heart failure: mechanisms of action and recent clinical developments. N. Engl. J. Med. 1986; 314: 349–358
   Google Scholar
• Arnold J. M.O. The role of Phoshpodiesterase inhibitors in heart failure. Pharmacol. Thera. 1993; 57: 161–170
   PubMedGoogle Scholar
• Captoril-Digoxin Multicenter Research Group. Comparative effects of therapy with captoril and digoxin in patients with mild to moderate heart failure. JAMA 1988; 259: 539–550
   Google Scholar
• Massie B., Bourassa M., DiBianco R., Hess M., Konstam M., Linkoff M., Packer M. Long-term oral administration of amrinone for congestive heart failure: Lack of efficacy in a multicenter controlled trial. Circulation 1985; 7: 963–971
   Google Scholar
• The Promise Study Research Group. Effect of oral milrinone on mortality in severe chronic heart failure. N. Engl. J. Med. 1991; 21: 1468–1510
   Google Scholar
• Uretsky B. F., Jessup M., Konstam M. A., Dei G. W., Leier C. V., Benotti J., Murali S., Herrmann H. C., Sandberg J. A. Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure: Lack of benefit compared to placebo. Circulation 1990; 82: 774–780
   PubMed Web of Science ®Google Scholar
• The Pimobendan Multicenter Research Group. Beneficial effects of pimobendan on exercise tolerance and quality of life in patints with heart failure. Circulation 1992; 85: 942–949
   Google Scholar
• Thompson W. J. Cyclic nucleotide phosphodiesterases: Interrelationships of pharmacology, biochemistry and function. Pharmacol. and Therapeutics 1991; 51: 13–33
   PubMed Web of Science ®Google Scholar
• Kithas P. A., Artman M., Thompson W. J., Strada S. J. Subcellular distribution of high-affinity typelV cyclic AMP phosphodiesterase activity in rabbit ventricular myocardium: relations to the effect of cardiotonic drugs. Circulation Res. 1988; 62: 782–789
   Google Scholar
• Venuti M. C., Jones G. H., Alvarez R., Bruno J. J. Inhibition of cyclic AMP phosphodiesterase. J. Med. Chem. 1987; 30: 303–318
   Google Scholar
• Alvarez R. G., Banerjee L., Bruno J. J., Jones G. L., Liittschwager K., Strosberg A. M., Venuti M. C. A potent and selective inhibitor of cyclic AMP phosphodiesterase with potential cardiotonic and antithrombotic properties. Mol. Pharm. 1986; 29: 554–560
   PubMed Web of Science ®Google Scholar
• Kauffman R. F., Crowe V. G., Utterback B. G., Robertson D. W. LY195115: a potent, selective inhibitor of cyclic nucleotide phosphodiesterase located in sarcoplasmic reticulum. Mol. Pharm. 1986; 30: 609–616
   PubMed Web of Science ®Google Scholar
• Weishaar R. E., Kobylarz-Singer D. C., Kaplan H. R. Subclasses of cyclic AMP phosphodiesterase in cardiac muscle. J. Mol. Cell. Cardiol. 1987; 19: 1025–1036
   Google Scholar
• Moos W. H., Humblet C. C., Silcar I., Rithner C., Weishaar R. E., Bristol J. A., McPhail A. T. Cardiotonic agents. 8: Selective inhibitors of adenosine 3p5p-cyclic AMP phosphodiesterase III; Elabolation of a five-point model for positive inotropic activity. J. Med. Chem. 1987; y: 30:1963–1972
   Google Scholar
• Venuti M. C., Stephenson R. A., Alvarez R., Bruno J. J., Strosberg A. M. Inhibitiors of cyclic AMP phosphodiesterase. 3. Synthesis and biological evaluation of pyrido and imidazolyl analogues of 1,2,3,5-tetrahydro-2-oxoimidazo[2,1-b]quinazolin. J. Med. Chem. 1988; 31: 2136–2145
   Google Scholar
• Hayes J. S., Pollock G. D., Wilson H., Bowling N., Robertson D. W. Pharmacology of LY195115, a potent orally active cardiotonic with a long duration of action. J. Cardiovasc. Pharmacol. 1987; 9: 4:425–434
   Google Scholar
• Kauffman R. F., Utterback B. G., Robertson D. W. Characterization and pharmacological relevance of high affinity binding sites for [3H]LY186126, a cardiotonic phosphodiesterase inhibitor in canine cardiac membranes. Circulation Res. 1989; 65: 154–163
   PubMed Web of Science ®Google Scholar
• Artman M., Robertson D. W., Mahony L., Thompson W. J. Analysis of the binding sites for the cardiotonic phosphodiesterase inhibitor [3H]LY186126 in ventricular myocardium. Mol. Pharmacol. 1989; 36: 302–311
   Google Scholar
• Robertson D. W., Krushinski J. H., Utterback B. G., Kauffman R. F. Synthesis of a tritium-labelled analogue and its use as a radioligand for phosphodiesterase-inhibitor cardiotonic bindingsites. J. Med. Chem. 1989; 32: 1476–1480
   Google Scholar
• Thompson W. J., Epstein P. M., Strada S. J. Purification and characterization of a high affinity cyclic adenosine monophosphate phosphodiesterase from dog kidney. Biochemistry 1979; 18: 5228–5327
   Google Scholar
• Robertson D. W., Krushinski J. H., Beedle E. E., Wyss V., Pollock G. D., Wilson H, Kauffman RF, Hayes JS. Dihydropyridazinone cardiotonics: The discovery and inotropic activity of 1,3-dihydro-3,3-dimethyl-5-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)-2H-indol-2-one. J. Med. Cheim. 1986; 29: 1832–1840
   PubMed Web of Science ®Google Scholar
• Jones L. R., Cala S. E. Biochemical evidence for functional heterogeneity of cardiac sarcoplasmic reticulum vesicles. J. Biol. Chem. 1981; 256: 11809–11818
   PubMedGoogle Scholar
• Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976; 72: 660–672
   Google Scholar
• Thompson W. J., Appleman M. M. Multiple cyclic nucleotide phosphodiesterase activities from rat brain. Biochemistry 1971; 10: 311–316
   PubMed Web of Science ®Google Scholar
• Beavo J. A., Reinfsnyder D. H. Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors. TIPS 1990; 11: 150–155
   PubMed Web of Science ®Google Scholar
• Burkert U., Allinger N. L. Molecular Mechanics. ACS monograph 177, American Chemical Society, Washington, DC 1982
   Google Scholar
• Tai J. C., Allinger N. L. Molecular mechanics calculations on conjugated nitrogen-cotaining heterocycle. J. Am. Chem. Soc. 1988; 110: 2050–2055
   Web of Science ®Google Scholar
• Rodbard D., Hutt D. M. Statistical analysis of radioimmunoassay and immunoradiometric (labelled antibody) assays: a generalized weighed, iterative least squres method for logistic curve fitting, in Proceeding, Symposium on Radioimmnnoassay and Related Procedures in Medicine (International Atomic Energy Agency, Vienna, Austria). Unipub. New York. 1974; 165–192
   Google Scholar
• Strada S. J., Kithas P. A., Whalin M. E., Thompson W. J. Molecular properties of cyclic nucleotide phosphodiesterase isozymes. Calcium Proteins in Health and Diseases 1989; 409–423
   Google Scholar
• Utterback S. A., Robertson D. W., Kauffman R. F. Identification of a high affinity binding site for cardiotonic phosphodiesterase inhibitors in sarcoplasmic reticulum (SR) vesicles. FASEB J. 1988; 2: A1817
   Google Scholar
• Robertson D. W., Boyd D. B. Structural requirement for potent and selective inhibition of low-Km Cyclic AMP Specific Phosphodiesterase. Adv. Sec. Mess. Phosphopro. Res. 1991; 26: 321–340
   Google Scholar
• Robertson D. W., Jones N. D., Krushinski J. H., Pollock G. D., Swartzendruber J. K., Haynes J. S. Molecular structure of the dihydropyridazinone cardiotonic 1,3-dihydro-3,3-dimethyl-5-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)-2H-indol-2-one, a potent inhibitor of cyclic AMP phosphodiesterase. J. Med. Chem. 1987; 30: 623–637
   PubMed Web of Science ®Google Scholar
• Erhardt P. W., Chou Y. L. A topographical model for the c-AMP phosphodiesterase III active site. Life Sciences 1991; 49: 553–568
   Google Scholar
• Sircar I., Weishaar R.E., Kobylarz D., Moos W.H., Bristol J.A. Cardiotonic agents. 7. Inhibition of separated forms of cyclic nucleotide phosphodiesterase from guinea pig cardiac muscle by 4,5-dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones and related compounds. Structure-Activity Relationships and Correlation with in Vivo Positive Inotropic Activity. J. Med. Chem. 1987; 30: 1955–1962
   PubMed Web of Science ®Google Scholar